Liver Function Tests: Nursing Guide
Liver function tests (LFTs) are a grouped blood panel — not one test — that nurses review for hepatocellular, cholestatic, and synthetic patterns using ALT, AST, ALP, bilirubin, albumin, and coagulation markers. Pair the full panel with symptoms, medicine exposure, and trends; normal values do not always rule out liver disease, and one elevated enzyme rarely confirms a diagnosis alone.
Contents
Quick Facts
Key Takeaway
LFTs answer pattern questions — hepatocellular versus cholestatic versus synthetic dysfunction — when ALT, AST, ALP, bilirubin, albumin, and INR are read together with symptoms and trends.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Serum separator (gold-top) per many laboratory protocols
Verify local tube, additive, and serum vs plasma requirements
Serum or plasma (venous blood)
Typically one venous draw for a hepatic panel — volume per institutional phlebotomy protocol
Routine venous draw; fasting may be required when ordered with CMP or lipid studies
May be required when LFTs are bundled with fasting CMP or lipid panel — follow ordering clinician and laboratory instructions; isolated LFT components usually need no special prep
Label promptly; transport per laboratory policy; avoid hemolysis and prolonged delay
Turnaround and screening rules vary by institution; follow local policy — often same-day when run with routine chemistry
Clinical chemistry / liver function panel
What is Liver Function Tests?
Liver Function Tests are blood tests that measure liver-related enzymes, bilirubin, proteins, and sometimes coagulation markers to assess hepatocellular injury, bile flow (cholestasis), and synthetic liver function. Common panel components include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin, and albumin. Clinicians may add prothrombin time/INR when evaluating synthetic function. The panel is ordered during jaundice workups, hepatitis monitoring, medicine safety review, and cirrhosis surveillance.
Overview
Nurses encounter LFTs in preoperative screening, jaundice and RUQ pain pathways, viral hepatitis follow-up, statin or hepatotoxic medicine monitoring, and known cirrhosis care. Because patients may have biochemical injury before obvious symptoms — or normal panels at some stages of disease — trend review and symptom correlation matter as much as a single result flag.
NIH standard clinical references and NHS guidance emphasize that liver function tests must be interpreted as a pattern with the clinical picture; they do not by themselves diagnose a specific cause. The American College of Gastroenterology abnormal liver chemistries guideline supports evaluating hepatocellular and cholestatic patterns with appropriate follow-up testing rather than reacting to one isolated value.
Before collection, verify the ordered panel components (full LFT vs CMP vs isolated tests), fasting requirements, and hepatotoxic exposures including acetaminophen, alcohol, herbal products, and statins. After results return, classify the pattern (hepatocellular, cholestatic, mixed, or synthetic dysfunction), compare to prior values, and escalate new encephalopathy, bleeding, or rapidly rising enzymes per facility policy.
Panel Pattern Recognition and Acute Liver Escalation Safety
LFTs are ordered so often that nurses may react to one flagged enzyme instead of the full pattern. Hepatocellular injury (disproportionate ALT/AST rise), cholestasis (ALP/GGT/bilirubin rise), and synthetic dysfunction (low albumin, prolonged INR) carry different urgency. Normal panels do not always exclude liver disease — always pair results with symptoms, medicines, alcohol exposure, and trends.
- Critical ALT/AST with rising bilirubin, INR, or encephalopathy signs — possible acute liver failure pathway
- Cholestatic pattern with fever, hypotension, and RUQ pain — possible cholangitis or biliary sepsis workup
- Continued hepatotoxic medicine after marked LFT rise without prescriber review
- Reassuring the patient because a prior panel was normal while jaundice and enzymes are rising now
Document: full panel values with reference intervals, pattern interpretation, medicine/alcohol exposure, symptoms, prescriber notification, pending imaging/serology, and patient teaching.
What a Liver Function Panel Can and Cannot Tell You
This test can help identify:
- Biochemical evidence of hepatocellular injury when ALT/AST rise out of proportion to ALP
- Cholestatic or biliary patterns when ALP, GGT, and bilirubin rise together
- Possible synthetic dysfunction when albumin falls or INR prolongs with clinical signs
- Need for imaging, hepatitis serology, hepatology referral, or repeat trend testing
This test cannot:
- Diagnose hepatitis type, obstruction site, cirrhosis stage, or fibrosis by itself
- Replace abdominal ultrasound, MRCP, elastography, or biopsy when structural disease is suspected
- Rule out liver disease when all values are normal — NHS notes tests may be normal at some stages
- Prove medication nonadherence or alcohol relapse without history, symptoms, and trend review
Pre-draw Checks for Liver Function Panels
Verify
Clarify before proceeding when:
- Order is unclear (isolated ALT vs full hepatic panel vs CMP only)
- Fasting status conflicts with MAR when fasting panel required
- Visible jaundice with hemodynamic instability before routine outpatient draw
- Prior critical LFT notification pending without prescriber acknowledgment
- Result conflicts with obvious cholestasis signs (pale stool, pruritus) and “normal” total bilirubin
- Patient identity or specimen label mismatch
- Hemolyzed or rejected specimen — confirm repeat collection before discharge
Hepatocellular, Cholestatic, and Mixed LFT Patterns
Nurses support safe interpretation by labeling the dominant pattern and communicating it with values and trends — not by diagnosing etiology at the bedside. ACG and standard clinical references describe hepatocellular injury when aminotransferases rise disproportionately; cholestasis when ALP and bilirubin dominate; mixed patterns when both arms elevate. Review synthetic markers (INR, albumin) when encephalopathy or bleeding is suspected.
| Pattern | Typical panel clue | Nursing focus |
|---|---|---|
| Hepatocellular | ALT/AST rise > ALP; rising bilirubin in severe injury | Notify prescriber for acute rise; review hepatotoxic medicines; monitor mental status |
| Cholestatic | ALP/GGT/bilirubin rise > ALT/AST | Support imaging; monitor fever, pruritus, and pain; escalate sepsis signs |
| Mixed | Both aminotransferases and cholestatic markers elevated | Communicate full pattern; avoid focusing on one analyte |
| Isolated hyperbilirubinemia | Bilirubin elevated with minimal enzyme change | Clarify fractionation order; correlate urine/stool color and hemolysis workup |
| Synthetic dysfunction | Low albumin and/or prolonged INR with clinical decompensation | Escalate per protocol; prepare for specialist review |
Reference ranges and critical values may vary by laboratory, institution, analyzer, age, sex, pregnancy status, and clinical context. Always interpret results using the reporting laboratory’s reference range and local escalation policy.
LFT Monitoring in Acute and Chronic Care Pathways
Diagnostic safety badge: Critical-result test — prompt review and escalation may be required when institution-defined chemistry critical values, acute LFT rise, or clinical deterioration are present.
Check-before-test protocol
- Identity + order + fasting requirement for full panel
- Symptom baseline: jaundice, pain, mental status, urine/stool color
- Medicine, alcohol, and herbal exposure documented
- Correct tube and laboratory transport
- Plan for pattern review with prior LFTs and synthetic markers
Critical teach-back questions
- “Can you tell me why we are checking several liver blood tests together?”
- “What symptoms such as yellow skin, confusion, bleeding, dark urine, or severe belly pain should you report right away?”
- “Can you tell me whether fasting or medicine changes were requested before this blood work?”
Care coordination: prescriber, laboratory, phlebotomy, medical imaging, hepatology, gastroenterology, pharmacy, addiction medicine, and rapid response per institutional protocol.
Why Liver Function Tests is Ordered
LFTs are ordered when clinicians need to screen for liver injury, classify abnormal liver chemistries, monitor known disease, or evaluate symptoms suggesting hepatobiliary disease.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Jaundice, pruritus, or RUQ pain | Is there hepatocellular or cholestatic biochemical injury? | Pattern review of ALT/AST, ALP, GGT, and bilirubin guides urgent imaging or hepatitis workup per clinical guidelines. |
| Suspected or known viral hepatitis | Is liver inflammation stable, improving, or worsening? | Serial LFT trends support monitoring hepatitis C and other hepatitis pathways alongside serology and symptoms. |
| Medicine or alcohol-related liver injury monitoring | Is there rising hepatocellular or cholestatic enzyme release on therapy? | Trending ALT/AST and bilirubin support hold-or-adjust decisions for hepatotoxic medicines and evaluation of alcoholic hepatitis when clinically suspected. |
| Metabolic liver disease and cirrhosis surveillance | Is synthetic function stable alongside enzyme trends? | Panel review with albumin and INR supports monitoring MASLD and chronic liver disease progression. |
Contraindications and Precautions
Venous blood draw for LFTs has few true contraindications. Nursing focus is on safe phlebotomy, correct specimen handling, and avoiding over-interpretation of isolated results.
- Rapidly rising ALT/AST or cholestatic panel with jaundice, fever, hypotension, or altered mental status — escalate according to facility policy.
- Suspected acute liver failure pattern (marked enzyme rise with coagulopathy, encephalopathy, or hypoglycemia) — notify prescriber and rapid response per protocol.
- Continued hepatotoxic medicine exposure after significant LFT rise without prescriber review — clarify hold instructions before next dose when ordered.
- Hemolyzed specimens may affect chemistry quality — recollect if sample is rejected per laboratory guidance.
- Normal LFTs do not exclude liver disease — NHS notes tests can be normal at many disease stages; symptoms and trends still matter.
- Isolated mild elevations may reflect medicines, exercise, or transient illness — avoid labeling without pattern review and repeat testing when indicated.
- New or worsening jaundice, ascites, encephalopathy, or GI bleeding with abnormal LFT pattern
- ALT/AST or cholestatic markers trending upward on serial testing with systemic deterioration
- Any LFT analyte flagged critical per local laboratory policy — communicate with read-back if required and document notification
Patient Preparation
Special preparation for isolated LFT components is usually minimal. Preparation often focuses on fasting for bundled panels, medicine and alcohol review, and symptoms that change interpretation.
Pre-test checksReview medicines with the prescriber and pharmacy as needed. standard clinical references and LiverTox note acetaminophen, statins, antibiotics, anticonvulsants, methotrexate, and other hepatotoxic drugs may affect LFT components. Do not stop medicines unless the prescriber instructs.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Liver Function Tests. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
LFT components are reported with the reporting laboratory’s units and reference intervals. Interpretation depends on pattern (hepatocellular, cholestatic, mixed, isolated hyperbilirubinemia, synthetic dysfunction), symptoms, medicines, alcohol exposure, and trends — not universal thresholds.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within reference interval | All ordered components within reporting laboratory reference intervals | No current pattern suggesting marked hepatobiliary injury in clinical context — still correlate with symptoms per NHS guidance | Continue routine monitoring if clinically indicated; do not dismiss symptoms solely because the panel is normal |
| Borderline / near reference limit | One or more components just above or below reference interval | May reflect medicines, transient illness, or early injury — trend and full pattern review matter | Review prior results, exposure history, and symptoms; communicate persistent borderline patterns to prescriber |
| High / above reference interval | One or more components above reference interval | Possible hepatocellular injury, cholestasis, medicine effect, viral hepatitis, obstruction, or other causes listed in reviewed references — pattern determines urgency | Classify pattern; review albumin/INR if available; notify prescriber; support ordered imaging, serology, or specialist follow-up |
| Low / below reference interval | Albumin or other components below reference interval (when applicable) | May suggest synthetic dysfunction, malnutrition, or chronic liver disease — requires clinical correlation with INR and examination | Communicate low albumin or prolonged coagulation markers with symptoms; avoid false reassurance |
Critical LFT Patterns and Escalation
Universal numeric critical thresholds for every LFT analyte are Turnaround and screening rules vary by institution; follow local institutional policy. Many institutions define critical values locally. Escalate when any component is markedly abnormal per laboratory flag, especially with jaundice, encephalopathy, coagulopathy, sepsis signs, or rapid upward trend across the panel.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Acute hepatocellular injury pattern | Markedly elevated ALT/AST with rising bilirubin, coagulopathy, or altered mental status | Notify prescriber urgently; prepare for acute liver failure pathway and ammonia review if encephalopathy suspected per protocol |
| Cholestatic pattern with systemic illness | Rising ALP/GGT/bilirubin with fever, hypotension, RUQ pain, or pruritus | Escalate according to facility policy; support ordered biliary imaging and blood cultures if sepsis suspected |
| Critical value notification per local policy | Any LFT analyte meeting institutional critical-value criteria | Perform read-back if required, document time and recipient, and monitor patient closely |
Stop routine reassurances and escalate according to facility policy when the patient develops jaundice with fever and hypotension, sudden severe abdominal pain, confusion, bleeding, hypoglycemia, or when LFT trends conflict with a stable clinical appearance.
Factors Affecting Results
LFT components are affected by medicines, alcohol, hemolysis, fasting status, pregnancy, muscle injury (AST), bone disease (ALP), and pre-analytic specimen quality. Nurses should flag factors that may mislead pattern interpretation.
- Isolated mild ALT rise from recent exercise, obesity, or non-hepatotoxic medicines
- ALP elevation from bone growth, pregnancy, or bone disease without hepatobiliary injury
- Hemolysis or lab error falsely suggesting hepatocellular injury on repeat review
- Normal LFT panel does not exclude liver disease — NHS and standard clinical references emphasize clinical context and stage of disease
- Missing bilirubin fractionation or GGT when ALP is elevated — cholestasis or bone source may be unclear
- Reviewing only ALT while ignoring albumin and INR in cirrhosis surveillance
- Hemolysis, delayed transport, or incorrect tube
- Hepatotoxic medicines and alcohol exposure
- Non-fasting draw when companion lipids or glucose require fasting
LFTs cannot diagnose the specific cause of liver disease, localize obstruction, or stage fibrosis by themselves. Normal values may occur at some disease stages. Imaging, serology, elastography, or biopsy may be required per ACG and standard clinical references guidance.
Nursing Responsibilities
Nursing responsibilities focus on correct collection, exposure history, pattern recognition, prescriber communication, and balanced patient teaching about follow-up testing.
Before the TestDocumentation
Documentation should support pattern interpretation and communication when LFTs are abnormal or trending.
“Venipuncture left antecubital fossa; 1 attempt; fasting x 10 h per CMP order. Specimen sent to lab 0810. Patient reports extra OTC acetaminophen over three days. LFT panel: ALT 620 U/L (H), AST 540 U/L (H), ALP 210 U/L (H), total bilirubin 3.8 mg/dL (H), albumin 3.0 g/dL (L), INR 1.8 (H); prior panel normal two weeks ago. Prescriber notified 0845, read-back completed. Patient jaundiced, no encephalopathy; N-acetylcysteine pathway initiated per order. Teaching reinforced on reporting confusion or bleeding.”
- Date, time, site, fasting status, and panel components ordered
- Key values with laboratory reference intervals and critical flags
- Pattern label (hepatocellular/cholestatic/mixed) and trend comparison
- Medicine, alcohol, and herbal exposure documented
- Prescriber notification and read-back per policy
- Patient teaching and pending follow-up tests or imaging
Patient and Family Education
Patients may worry that abnormal LFTs mean permanent liver failure. Use clear, non-stigmatizing language without false reassurance — explain that patterns and follow-up tests clarify cause.
Liver Function Tests NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Liver Function Tests safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: LFT panel — acute jaundice and hepatotoxic medicine exposure
- Indication: Progressive jaundice and RUQ discomfort; evaluate acute liver injury
- Timing: Morning fasting CMP with hepatic panel; repeat LFTs ordered in 24 h
- Related orders: Liver function tests; acetaminophen level if available; coagulation studies; hepatitis serology pending
- Result: ALT 850 U/L (critical high), AST 720 U/L (critical high), ALP 195 U/L (H), total bilirubin 4.1 mg/dL (H), albumin 3.1 g/dL (L), INR 1.9 (H); prior LFTs normal two weeks ago
- Trend / prior value: ALT and AST rising sharply over 48 h; bilirubin and INR trending up; albumin down from prior panel
- Pending tests: Hepatitis serology not yet resulted; acetaminophen level pending
- Vital signs: HR 104/min, BP 98/62 mmHg, RR 20/min, SpO₂ 95% on room air, temp 37.6°C
- Symptoms: Scleral icterus, RUQ tenderness, nausea, reports dark urine; no reported hematemesis
- Focused assessment: Alert but fatigued; skin jaundiced; mild asterixis not noted; reports extra OTC pain relievers
- Preparation notes: Patient took maximum daily acetaminophen for three days; fasting status confirmed for CMP draw
- Collection events: Specimen labeled correctly; no hemolysis; colleague suggested waiting for serology before any prescriber contact
- Teaching gaps / safety concerns: Critical hepatocellular pattern with rising INR, jaundice, hypotension trend, and continued acetaminophen on MAR until clarified
Answer key & rationale
Frequently Asked Questions
FAQ
What tests are included in liver function tests?
Panels vary by institution but often include ALT, AST, ALP, GGT, bilirubin, and albumin. Clinicians may add INR or prothrombin time for synthetic function. LFTs as a group of blood tests that check liver health — not a single analyte.
Does the patient need to fast before LFTs?
Isolated LFT components usually do not require special preparation. When LFTs are ordered with a fasting CMP or lipid panel, fasting may be required — follow the ordering clinician and laboratory instructions.
What does an abnormal LFT result mean?
Abnormal results suggest possible hepatocellular injury, cholestasis, medicine effects, or other liver conditions — interpreted as a pattern with symptoms and trends. One elevated value alone cannot confirm a specific diagnosis and ACG guidance.
Can normal LFTs rule out liver disease?
No. NHS guidance liver function tests can be normal at many stages of liver disease. Nurses should still correlate symptoms, medicines, alcohol use, and trends with the clinical picture.
What is the difference between hepatocellular and cholestatic patterns?
Hepatocellular patterns show disproportionate ALT/AST elevation; cholestatic patterns show disproportionate ALP, GGT, and bilirubin rise. Mixed patterns occur. Nurses support prescriber review and ordered imaging or serology — not bedside diagnosis alone.
When should nurses escalate LFT results?
Escalate when any component is markedly elevated or flagged critical per local policy, especially with jaundice, encephalopathy, bleeding, fever, abdominal pain, or rapid upward trend — according to facility protocol.
What medicines commonly affect LFT results?
standard clinical references and NIH LiverTox list acetaminophen, statins, antibiotics, methotrexate, and many other medicines that may injure the liver or raise enzymes. Review the MAR with the prescriber; do not stop medicines without an order.
References
References
-
U.S. National Library of Medicine. Liver Function Tests. MedlinePlus Medical Test.https://medlineplus.gov/lab-tests/liver-function-tests/
-
Lala V; Zubair M; Minter DA. Liver Function Tests. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.https://www.ncbi.nlm.nih.gov/books/NBK482489/
-
Kwo PY; Cohen SM; Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35.https://doi.org/10.1038/ajg.2016.517
-
NHS. Liver function tests. NHS website.https://www.nhs.uk/conditions/liver-function-tests/
-
Saiman YS; Nguyen M. Laboratory Tests of the Liver and Gallbladder. Merck Manual Professional Edition.https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/testing-for-hepatic-and-biliary-disorders/laboratory-tests-of-the-liver-and-gallbladder
-
American College of Gastroenterology. Evaluation of Abnormal Liver Chemistries. ACG Clinical Guideline resource.https://gi.org/guideline/evaluation-of-abnormal-liver-chemistries/
-
National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox. NIDDK.https://www.ncbi.nlm.nih.gov/books/NBK5472/
-
U.S. National Library of Medicine. Bilirubin Test. MedlinePlus Medical Test.https://medlineplus.gov/lab-tests/bilirubin-test/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Liver Function Tests.
Policies: Medical Review Process · Editorial Policy · Correction Policy